Literature DB >> 22008640

Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Kevin A Henry1, Armstrong Murira, Nienke E van Houten, Jamie K Scott.   

Abstract

Filamentous bacteriophage are commonly used as immunogenic carriers for peptides and proteins displayed on the phage surface. Previously, we showed that immunization with phage to which peptides had been chemically conjugated can elicit a focused anti-peptide antibody response compared with traditional carrier molecules bearing the same peptide, perhaps due to the low surface complexity of the phage. The regularity of its surface also gives the phage other advantages as a carrier, including immunological simplicity and thousands of well-defined sites for chemical conjugation. More recently, we showed that focusing of antibody responses against 'target' peptides was enhanced when the phage's molecular surface was simplified by removal of immunodominant B-cell epitopes present on the minor coat protein, pIII. The pIII-truncated variant elicits an antibody response that is largely restricted to the exposed N-terminus of the major coat protein, pVIII, and to phage-associated bacterial lipopolysaccharide, and a significant fraction of this response cross-reacts with a 12-residue peptide covering the surface-exposed region of pVIII. This allows one to track antibody responses against the phage (and any associated haptens) as they develop over time, and characterize them using a combination of serological, flow cytometric, cellular and immunogenetic assays. The filamentous phage thus provides an excellent model system for studying various aspects of the antibody response, all with the goal of targeting antibody production against weakly immunogenic peptides, proteins and carbohydrates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008640      PMCID: PMC3225742          DOI: 10.4161/bbug.2.5.16559

Source DB:  PubMed          Journal:  Bioeng Bugs        ISSN: 1949-1018


  52 in total

Review 1.  B1 cells: similarities and differences with other B cell subsets.

Authors:  F Martin; J F Kearney
Journal:  Curr Opin Immunol       Date:  2001-04       Impact factor: 7.486

Review 2.  B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory".

Authors:  F Martin; J F Kearney
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

Review 3.  Engineering M13 for phage display.

Authors:  S S Sidhu
Journal:  Biomol Eng       Date:  2001-09

4.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Icosahedral virus particles as addressable nanoscale building blocks.

Authors:  Qian Wang; Tianwei Lin; Liang Tang; John E Johnson; M G Finn
Journal:  Angew Chem Int Ed Engl       Date:  2002-02-01       Impact factor: 15.336

6.  Homodimeric peptides displayed by the major coat protein of filamentous phage.

Authors:  M B Zwick; J Shen; J K Scott
Journal:  J Mol Biol       Date:  2000-07-07       Impact factor: 5.469

7.  Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.

Authors:  S M Cleveland; E Buratti; T D Jones; P North; F Baralle; L McLain; T McInerney; Z Durrani; N J Dimmock
Journal:  Virology       Date:  2000-01-05       Impact factor: 3.616

8.  Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.

Authors:  M B Zwick; L L Bonnycastle; A Menendez; M B Irving; C F Barbas; P W Parren; D R Burton; J K Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

9.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  7 in total

Review 1.  Filamentous bacteriophage fd as an antigen delivery system in vaccination.

Authors:  Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Int J Mol Sci       Date:  2012-04-24       Impact factor: 6.208

2.  FcRn overexpression in transgenic mice results in augmented APC activity and robust immune response with increased diversity of induced antibodies.

Authors:  Attila Végh; Anita Farkas; Dorottya Kövesdi; Krisztián Papp; Judit Cervenak; Zita Schneider; Balázs Bender; László Hiripi; Glória László; József Prechl; János Matkó; Imre Kacskovics
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

Review 3.  Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.

Authors:  Kyriakos A Hassapis; Dora C Stylianou; Leondios G Kostrikis
Journal:  Viruses       Date:  2014-12-17       Impact factor: 5.048

Review 4.  Arming Filamentous Bacteriophage, a Nature-Made Nanoparticle, for New Vaccine and Immunotherapeutic Strategies.

Authors:  Rossella Sartorius; Luciana D'Apice; Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

Review 5.  Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold.

Authors:  Kevin A Henry; Mehdi Arbabi-Ghahroudi; Jamie K Scott
Journal:  Front Microbiol       Date:  2015-08-04       Impact factor: 5.640

Review 6.  Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development.

Authors:  Tatiana I Samoylova; Timothy D Braden; Jennifer A Spencer; Frank F Bartol
Journal:  Curr Med Chem       Date:  2017-11-20       Impact factor: 4.530

7.  The development of inovirus-associated vector vaccines using phage-display technologies.

Authors:  Zachariah Stern; Dora C Stylianou; Leondios G Kostrikis
Journal:  Expert Rev Vaccines       Date:  2019-09-08       Impact factor: 5.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.